Citizens Initiates Coverage On Nasus Pharma with Market Outperform Rating, Announces Price Target of $19

Benzinga · 2d ago
Citizens analyst Jason Butler initiates coverage on Nasus Pharma (AMEX:NSRX) with a Market Outperform rating and announces Price Target of $19.